It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B

Drew Armstrong

Executive Editor

Nicole DeFeudis

Editor

In one of the biggest healthcare IPOs of the last decade, Johnson & Johnson’s consumer spinout Kenvue raised $3.8 billion and started trading on the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B

Drew Armstrong

Executive Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

It's IPO day for J&J's Ken­vue: Stock gains 20% in first day of trad­ing as unit rais­es $3.8B

Executive Editor

Editor

Sign up to read this article for free.

It's IPO day for J&J's Kenvue: Stock gains 20% in first day of trading as unit raises $3.8B